Ferroptosis In Neurodegeneration is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Ferroptosis is a regulated form of non-apoptotic cell death driven by iron-dependent lipid peroxidation. This pathway has emerged as a critical mechanism in neurodegenerative diseases, offering new therapeutic targets for neuroprotection.
Ferroptosis is morphologically and biochemically distinct from apoptosis, necrosis, and autophagy. It is characterized by iron accumulation, lipid peroxidation, and plasma membrane damage, leading to regulated necrotic cell death. Growing evidence implicates ferroptosis in Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS).
flowchart TD
A[Iron Overload] --> B[Fenton Chemistry] -->
A --> C[Ferritinophagy] -->
A --> D[Transferrin Receptor] -->
B --> E[Hydroxyl Radical Generation] -->
C --> E
D --> E
E --> F[Lipid Peroxidation] -->
F --> G[LOX Activation] -->
F --> H[ACS4 Activation] -->
F --> I[PUFA Incorporation] -->
G --> J[Membrane Damage] -->
H --> J
I --> J
J --> K[GPX4 Inactivation] -->
J --> L[CoQ10 Reduction] -->
K --> M[Programmed Necrosis] -->
L --> M
M --> N[Cell Death] -->
N --> O[Neuronal Loss] -->
O --> P[Neurodegeneration]
| Protein |
Function |
Changes in Neurodegeneration |
| Transferrin |
Iron transport |
Elevated in AD/PD brain |
| Transferrin Receptor |
Cellular iron uptake |
Increased expression |
| Ferritin |
Iron storage |
Altered H/L chain ratio |
| Ferroportin |
Iron export |
Mutations cause neurodegeneration |
| DMT1 |
Iron transporter |
Increased in substantia nigra |
- Blood-brain barrier: Tightly regulated iron entry
- Neuronal iron uptake: Transferrin-mediated endocytosis
- Glial iron handling: Ferritin storage in astrocytes
- Iron export: Ferroportin on neurons and glia
¶ Key Enzymes and Pathways
| Component |
Role |
Function |
| GPX4 |
Glutathione peroxidase |
Reduces lipid peroxides |
| ACSL4 |
Acyl-CoA synthetase |
Incorporates PUFAs into membranes |
| LOX |
Lipoxygenases |
Catalyzes lipid peroxidation |
| FSP1 |
Ferroptosis suppressor |
CoQ10-dependent inhibition |
| NCOA4 |
Cargo receptor |
Ferritinophagy |
- Arachidonic acid (AA)
- Adrenic acid (AdA)
- Docosahexaenoic acid (DHA)
- Membrane phospholipid incorporation
GSH → GPX4 → GSSG
↓
Reduced Lipids
- Cystine uptake via system Xc⁻
- Glutathione synthesis
- GPX4 as key regulator
- Increased brain iron: Age-related accumulation
- Ferritin changes: Altered iron storage
- Transferrin saturation: Increased free iron
- DMT1 upregulation: Enhanced iron entry
- Ferroportin dysfunction: Impaired export
| Approach |
Mechanism |
Status |
| Iron chelators |
Deferoxamine, Deferasirox |
Phase 2 trials |
| GPX4 activators |
Small molecule inducers |
Preclinical |
| LOX inhibitors |
Baicalein, Flavocoxid |
Preclinical |
| Liprostatin |
Lipid peroxidation inhibitor |
Preclinical |
- High iron content in SNc
- Neuromelanin-iron complex
- Dopaminergic neuron sensitivity
- Oxidative stress amplification
- Iron-mediated ROS: Fenton chemistry
- Lipid peroxidation: Membrane damage
- GPX4 reduction: Loss of protection
- Ferroptosis markers: Elevated in PD brain
- Mutant HTT affects iron metabolism
- Increased ferroptosis susceptibility
- Therapeutic potential of ferroptosis inhibitors
- Iron dysregulation in motor neurons
- GPX4 mutations linked to ALS
- Lipid peroxidation markers elevated
| Drug |
Mechanism |
Clinical Status |
| Deferoxamine |
Iron chelation |
Phase 2 (AD) |
| Deferasirox |
Oral iron chelator |
Phase 2 (PD) |
| Clioquinol |
Metal-protein attenuation |
Phase 3 |
| VK-28 |
Brain-penetrant chelator |
Preclinical |
- Liproxstatin-1: GPX4 stabilizer
- Ferrostatin-1: Radical trapping
- Vitamin E: Antioxidant
- CoQ10: Membrane protection
- Statins: Pleiotropic effects
- Minocycline: Multiple mechanisms
- Sulforaphane: Nrf2 activation
- Edaravone: Antioxidant (approved for ALS)
| Marker |
Source |
Significance |
| Ferritin |
Serum, CSF |
Iron storage status |
| Iron |
Serum, CSF |
Free iron levels |
| 4-HNE |
Brain tissue |
Lipid peroxidation |
| MDA |
Serum, CSF |
Oxidative stress |
| GPX4 activity |
Blood |
Ferroptosis regulation |
The study of Ferroptosis In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Dixon SJ, et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. PMID:22404938
- Stockwell BR, et al. (2017). Ferroptosis: A regulated cell death nexus linking metabolism, redox biology, and disease. Cell. PMID:28475899
- Conrad M (2020). Regulation of lipid, et al. peroxidation and ferroptosis in diverse biological contexts. Antioxid Redox Signal. PMID:32048815
- Hambright WS, et al. (2017). Ablation of ferroptosis regulator glutathione peroxidase 4 in forebrain neurons promotes cognitive impairment and neurodegeneration. Redox Biol. PMID:28818747
- Weiland A, et al. (2019). Ferroptosis and its role in neurodegenerative diseases. Acta Neuropathol Commun. PMID:31186041
- Mahoney-Sanchez L, et al. (2021). Ferroptosis and its role in neurodegenerative diseases. Int J Mol Sci. PMID:34066276
- Do Van B, et al. (2016). Ferroptosis, a newly characterized form of cell death in Parkinson's disease. J Neural Transm. PMID:26566699
- Agrawal S, et al. (2018). Ferroptosis: a process of regulated cell death in neurodegeneration. J Neurochem. PMID:29575723
- Masaldan S, et al. (2019). Iron accumulation in neurodegeneration. Brain Res. PMID:30684486
- Li J, et al. (2021). Ferroptosis: past, present and future. Cell Death Dis. PMID:32080172
- Ratan RR. (2020). The chemical biology of ferroptosis in the central nervous system. Cell Chem Biol. PMID:32097654
- Kwon MY, et al. (2019). Ferroptosis and its role in intracellular signaling. BMB Rep. PMID:31018195
- Song X, et al. (2021). Ferroptosis and its role in cancer therapy. J Cell Mol Med. PMID:33641146
- Bayır H, et al. (2020). Emerging targets for ferroptosis in neurobiology. Neurobiol Dis. PMID:32371267
- Zheng J, Conrad M. (2020). The metabolic underpinnings of ferroptosis. Cell Metab. PMID:32045383
🔴 Low Confidence
| Dimension |
Score |
| Supporting Studies |
15 references |
| Replication |
0% |
| Effect Sizes |
25% |
| Contradicting Evidence |
0% |
| Mechanistic Completeness |
50% |
Overall Confidence: 38%